Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study).

Shun IshiyamaTakeshi YamadaMasato NakamuraMasanobu EnomotoKiichi SugimotoHajime YokomizoChihiro KosugiRyo OhtaKei IshimaruHiromichi SonodaKeiichiro IshibashiHidekazu KuramochiYoichiro YoshidaDaisuke IchikawaKeiji HirataHiroshi YoshidaYojiro HashiguchiHideyuki IshidaKeiji KodaKenji KatsumataKazuhiro Sakamoto

Published in: International journal of clinical oncology (2022)

Regorafenib dose-escalation therapy is well tolerated with PFS-like regorafenib standard therapy.

Keyphrases

metastatic colorectal cancer
open label
stem cells
clinical trial
cell therapy
study protocol